ARRIGO, Mattia, Jiří PAŘENICA, Eva GANOVSKÁ, Marie PAVLUSOVA and Alexander MEBAZAA. Plasma bio-adrenomedullin is a marker of acute heart failure severity in patients with acute coronary syndrome. IJC HEART & VASCULATURE. CLARE: ELSEVIER IRELAND LTD, 2019, vol. 22, MAR 2019, p. 174-176. ISSN 2352-9067. Available from: https://dx.doi.org/10.1016/j.ijcha.2019.02.011.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Plasma bio-adrenomedullin is a marker of acute heart failure severity in patients with acute coronary syndrome
Authors ARRIGO, Mattia (250 France, guarantor), Jiří PAŘENICA (203 Czech Republic, belonging to the institution), Eva GANOVSKÁ (703 Slovakia), Marie PAVLUSOVA (203 Czech Republic) and Alexander MEBAZAA (250 France).
Edition IJC HEART & VASCULATURE, CLARE, ELSEVIER IRELAND LTD, 2019, 2352-9067.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30201 Cardiac and Cardiovascular systems
Country of publisher Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
RIV identification code RIV/00216224:14110/19:00109543
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1016/j.ijcha.2019.02.011
UT WoS 000462184100037
Keywords in English Bio-adrenomedullin; Acute coronary syndrome; Acute heart failure; Pulmonary edema
Tags 14110211, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 11/5/2020 09:13.
Abstract
Background: The assessment of acute heart failure (AHF) in patients with acute coronary syndrome (ACS) is challenging. This study tested whether measuring plasma adrenomedullin in patients admitted for ACS provides valuable information regarding the presence of AHF at admission or its occurrence during hospitalization. Methods and results: The study population consisted of 927 prospectively enrolled patients with ACS. Blood samples for the measurement of plasma bio-adrenomedullin (bio-ADM) were collected at admission. Patients with alveolar pulmonary edema and interstitial pulmonary edema on chest radiography at admission had step-wise higher plasma concentrations of bio-ADM compared to patients with no or mild pulmonary congestion: 54.3 +/- 10.6 vs. 27.6 +/- 2.1 vs. 22.5 +/- 0.7 ng/L, overall P < 0.001. Patients with ACS complicated by AHF during the index hospitalization displayed higher plasma bio-ADM concentrations at admission compared to patients without AHF (33.8 +/- 2.7 vs. 21.8 +/- 0.7, P < 0.001): the higher the severity of AHF, the higher plasma bio-ADM concentrations at admission. Patients with cardiogenic shock displayed the highest values. Accordingly, bio-ADM concentrations at admission were associated with a higher risk of occurrence of AHF during index hospitalization (odds ratio 1.018, 95% confidence interval 1.011-1.026, P < 0.001). Conclusions: Plasma adrenomedullin is a marker associated with AHF severity in patients with ACS. (c) 2019 Published by Elsevier B.V.
Links
MUNI/A/1250/2017, interní kód MUName: Validace Rule-out/rule-in protokolu u pacientů s bolestí na hrudi – pokračování v prospektivní studii
Investor: Masaryk University, Category A
PrintDisplayed: 28/8/2024 03:15